Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
British Journal of Cancer|October 14, 2005
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instabilityS L Smith, N L Bowers, D C Betticher, et al.International Journal of Cancer|August 5, 2000
Bcl-xl antisense treatment induces apoptosis in breast carcinoma cellsA P Simões-Wüst, R A Olie, O Gautschi, et al.International Journal of Cancer|May 8, 2000
Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatmentS H Leech, R A Olie, O Gautschi, et al.Respiration; International Review of Thoracic Diseases|January 25, 2014
Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screeningT Frauenfelder, M A Puhan, R Lazor, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2020
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in SwitzerlandC M Panje, J E Lupatsch, M Barbier, et al.Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort studyS Schmid, D Klingbiel, S Aeppli, et al.Pneumologie (Stuttgart, Germany)|November 9, 2018
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]F Griesinger, S Radke, A Lüers, et al.Cancer Immunology, Immunotherapy : CII|August 9, 2020
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 studyM A Amrein, E D Bührer, M L Amrein, et al.Journal of the National Cancer Institute|March 22, 2001
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic originsO Gautschi, S Tschopp, R A Olie, et al.Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.Pageof 3